Retatrutide Dosage: The Complete Trial Chart From 2mg to 12mg

Every retatrutide dosage figure worth trusting comes from one place: the published clinical trials. This guide sets out the retatrutide dosage schedules those studies actually used, the escalation logic behind them, the full retatrutide dosage chart from 2mg to 12mg, and how the amounts map onto the pen formats sold in the UK. It is research information, not medical guidance. Retatrutide holds no UK marketing authorisation and everything we stock is supplied for laboratory and research use only.

The Retatrutide Dosage Chart From the Trials

The Phase 2 obesity study randomised participants to target amounts of 1mg, 4mg, 8mg or 12mg weekly, reached through stepped escalation. This is the consolidated retatrutide dosage chart:

Three design choices stand out. Every arm above 1mg began at 2mg regardless of destination. No step doubled more than once per month. And the top retatrutide dosage of 12mg was only reached at week 13, a quarter of the way through the study. The published protocol treated escalation speed as a safety variable in its own right.

The Escalation Logic Explained

Why not start at the target retatrutide dosage directly? Because the compound activates three receptor systems at once, and the gastrointestinal side of that signalling needs adaptation time. The trials that compared faster and slower escalation to identical endpoints found the slower path cut nausea and dropouts substantially, results covered in our retatrutide side effects breakdown. The step pattern, four weeks minimum per level, exists because tolerance to incretin signalling builds over roughly that period. Skipping it does not speed up results, it multiplies the events that force people to stop entirely.

What Each Trial Arm Did, and Why It Matters

The 1mg arm functioned almost as an active control, producing modest changes. The 4mg arm delivered roughly 17 percent weight reduction at 48 weeks, already matching licensed single agonists. The 8mg arm reached roughly 22 percent, and the 12mg arm 24.2 percent, the headline figure. The increments between arms shrink as the retatrutide dosage rises: the step from 8mg to 12mg bought about two extra percentage points at the cost of visibly higher GI rates.

That plateau shape matters to anyone modelling protocols, because it says most of the effect arrives well below the maximum studied amount. Phase 3 TRIUMPH arms are concentrated in the 8mg to 12mg range for exactly this reason.

Mapping Retatrutide Dosage to UK Pen Sizes

UK research stock ships as 20mg and 40mg pens, so the trial schedules translate directly. A month at 2mg weekly consumes 8mg, under half a 20mg pen. A month at 4mg consumes 16mg, most of one. At 8mg weekly a month consumes 32mg, comfortably inside one 40mg pen kit, and the full 12mg schedule consumes 48mg, a 40mg kit plus part of a second pen. Buyers planning multi month research supply can find the cost side of this arithmetic in the retatrutide price guide and format details in the pen guide.

What Each Dosage Achieved at 48 Weeks

Common Retatrutide Dosage Misunderstandings

• Quoting the 12mg figure without the 13 week ramp. No trial participant started anywhere near the top amount.
• Reading milligrams across compounds. A milligram of retatrutide is not comparable to a milligram of semaglutide or tirzepatide; each compound has its own potency scale.
• Assuming more is proportionally better. The dose response curve flattens above 8mg while side effects keep climbing.
• Ignoring pen concentration. Research pens vary in concentration per click; the printed strength on the pen, not assumption, defines what a dial setting delivers.
• Treating trial schedules as guidance for use. They are published research protocols. Outside a regulated trial, retatrutide remains a research compound.

Dosing in the Diabetes Trials

The obesity study is the most quoted, but retatrutide was also studied in type 2 diabetes, and those protocols used a slightly different shape. Amounts of 0.5mg, 4mg, 8mg and 12mg weekly were tested over 36 weeks, with escalation again beginning low and stepping monthly. Glycaemic results tracked the same plateau pattern seen with weight: substantial improvement by 4mg, meaningful but diminishing additional benefit at 8mg and 12mg.

The practical takeaway for anyone reading across both programmes is that the compound behaves consistently, the dose response curve rises steeply through the low and middle range then flattens, and the escalation discipline is identical in both settings. Researchers citing a single headline figure without naming which programme it came from are usually mixing the two.

What Phase 3 TRIUMPH Is Testing

The Phase 3 TRIUMPH programme moved the focus to the 8mg and 12mg range, which is where Phase 2 showed the effect concentrating. Rather than exploring wider amounts, the trials are testing durability across longer periods, cardiovascular outcomes at scale and performance in specific populations including knee osteoarthritis and obstructive sleep apnoea cohorts. That design choice tells you what the manufacturer concluded from Phase 2: the useful retatrutide dosage window has already been found, and the remaining questions are about long term safety and outcomes rather than finding a higher ceiling.

Any regulatory submission to the MHRA will be built on these arms, which is why the licensing timeline runs to 2027 at the earliest.

Handling Accuracy at Low Amounts

One practical note that trial protocols handle invisibly but research work does not: accuracy at small amounts depends entirely on the delivery device. Early escalation steps of 2mg are a small fraction of a 40mg pen, and measurement error at that scale is proportionally larger than at 12mg. This is the strongest argument for pen format over vials in research settings, because a dial mechanism holds its increment accuracy where a syringe draw from a reconstituted vial depends on the operator. Pen concentration also varies between suppliers, so the printed strength on the device, not a remembered figure from another product, defines what any dial setting actually delivers.

Retatrutide Dosing, Dose and Dosage: The Same Chart, Three Words

People search this topic three different ways and mean the same thing, so it is worth stating plainly that retatrutide dosing, a retatrutide dose and retatrutide dosage all point at the chart above. There is no separate schedule hiding behind a different word. What varies is the level of detail each phrasing is usually looking for.

The one distinction worth drawing is between a dose and a dosing schedule. A dose is a single amount at a single point. A retatrutide dosing schedule is the sequence, and the sequence is what the trials actually tested. Every published result came from stepped escalation, never from starting at a target amount, which is why quoting a single dose without the schedule that led to it misrepresents what was studied.

That distinction matters practically as well. The tolerability profile reported in the trials belongs to the escalation, not to the endpoint amount. A retatrutide dosing approach that skips the steps is not a faster version of the published protocol, it is a different and unstudied one.

For how these amounts map onto what is actually sold in the UK, see the retatrutide 10mg guide for why the smallest pen rarely spans a useful period, the pen guide for dial increments and handling accuracy, and the price index for cost per milligram across formats.

What the Trials Did When an Amount Was Not Tolerated

The published retatrutide dosage schedules include a step that gets left out of almost every summary: what happened when a participant could not tolerate the next increase. The protocols did not simply push on. They allowed the escalation to pause at the current amount, and in some cases to step back down, before attempting the increase again later.

That matters because it changes how the headline results should be read. The reported outcomes at 48 weeks are not the outcomes of everyone reaching the top amount on schedule. They are the outcomes of a population in which some participants moved more slowly than the nominal chart implies, and others stopped short of the target entirely.

Discontinuation is the figure most worth holding onto. A meaningful share of participants across the higher arms did not complete, and that is part of the same dataset as the weight change headline. Reading one without the other overstates what the schedule delivers.

Why Small Amounts Are Harder to Measure Than They Look

At the low end of the schedule the practical limit is the device rather than the protocol. A pen dialling in half milligram steps cannot deliver a quarter milligram accurately, and priming errors matter proportionally more when the amount is small. An unprimed pen delivers less than the dial shows, which at 1mg is a large relative error and at 8mg is a small one.

• Prime the device exactly as its instructions specify before the first use, every time a new pen is opened.
• Match the increment to the amounts you actually need rather than buying whichever pen is cheapest.
• Record what was delivered rather than what was dialled, because the two differ when priming is skipped.
• Treat any figure derived from an unprimed first delivery as unreliable and exclude it.

Device increments and priming behaviour are compared across formats in the retatrutide pen guide.

Retatrutide Dosage FAQ